TCGA-A8-A07B-01A-11R-A00Z-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 44
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.440
- G2M_CHECKPOINT+0.420
- MYC_TARGETS_V2+0.410
- E2F_TARGETS+0.300
- MTORC1_SIGNALING+0.300
- UNFOLDED_PROTEIN_RESPONSE+0.280
- ANDROGEN_RESPONSE+0.270
- PROTEIN_SECRETION+0.260
- UV_RESPONSE_DN+0.240
- MITOTIC_SPINDLE+0.220
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.350
- INTERFERON_GAMMA_RESPONSE-0.320
- WNT_BETA_CATENIN_SIGNALING-0.300
- HEDGEHOG_SIGNALING-0.290
- IL2_STAT5_SIGNALING-0.260
- TNFA_SIGNALING_VIA_NFKB-0.250
- MYOGENESIS-0.220
- ALLOGRAFT_REJECTION-0.210
- BILE_ACID_METABOLISM-0.200
- IL6_JAK_STAT3_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | a7e776a3-4159-4cf7-8e05-2c2202330f58 | — | — | 0.822 |
| 2 | SJEPD030795_D3.RNA-Seq | EPN | Posterior Fossa EPN | 0.818 |
| 3 | MNG1168 | — | — | 0.799 |
| 4 | SRR25043634 | — | — | 0.792 |
| 5 | TCGA-BT-A20N-01A-11R-A14Y-07 | — | — | 0.792 |
| 6 | BS_4SCWT0FX | EPN | EPN Tumor | 0.791 |
| 7 | BS_TZ5D0A7R | EPN | Supratentorial EPN | 0.790 |
| 8 | SRR25043616 | — | — | 0.790 |
| 9 | MNG1194 | — | — | 0.788 |
| 10 | MNG592 | — | — | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.130 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.050 | Remibrutinib | — uncovered |
| HYPOXIA | 0.050 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.050 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.020 | Inavolisib | — uncovered |